Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.
Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to ...
ITM’s application rested on data from the phase 3 Compete trial in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These malignancies arise in a specialized group of neurons ...
Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have ...
Scholar Rock has shed Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a candidate for spinal muscular atrophy. The Cambridge, ...
Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound leading the pack, according to a survey of healthcare specialists by Spherix ...
It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...
Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...
News of the unconfirmed deal talks drew major investor pushback on AZ’s side, with the British drugmaker’s stock sliding nearly 9% following the Financial Times report. The company’s London-listed ...
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine. | Despite a major curveball thrown by the ...
Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results